BURLINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...
Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...
1h
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...
Bitcoin breaks below $90,000 as crypto selloff deepens. Apple, Indonesia reportedly agree on terms to end iPhone 16 ban. Drug ...
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Some e-cigarette companies targeted by U.S. authorities have altered their business model or changed their corporate ...
Barely a week after mass firings at the Food and Drug Administration, some probationary staffers received unexpected news over the weekend: The government wants them back. Beginning Friday night, FDA ...
A paper in the Journal of the National Cancer Institute finds that almost 20% of patients in middle-stage cancer drug trials ...
The US Food and Drug Administration’s new standards for foods before they can be labeled as “healthy” on their packaging will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback